Código QR (código de barras bidimensional)

Safety and tolerability of first‐line durvalumab with tremelimumab and chemotherapy in esophageal squamous cell carcinoma

Abstract Background Advanced or metastatic esophageal squamous cell carcinoma (ESCC) is associated with poor prognosis; new first‐line systemic treatment options are needed. Combining immuno‐oncology therapies with standard chemotherapy may represent a promising approach for the treatment of solid t...

ver descrição completa

Na minha lista:
Principais autores: Dae Ho Lee, Hye Ryun Kim, Bhumsuk Keam, Ken Kato, Yasutoshi Kuboki, Haiyan Gao, Alejandro Yovine, Scott H. Robbins, Myung‐Ju Ahn
Formato: Artigo
Idioma:Inglês
Publicado em: Wiley 2023-08-01
coleção:Cancer Medicine
Assuntos:
chemotherapy
clinical trials
esophageal squamous cell
immunology
Acesso em linha:https://doi.org/10.1002/cam4.6260
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados